PEG-IFNα
Sponsors
Assembly Biosciences, Vir Biotechnology, Inc., The Second Affiliated Hospital of Chongqing Medical University, Brii Biosciences Limited
Conditions
Anti-PD-1 AntibodyChronic Hepatitis BChronic Hepatitis B Virus (HBV) InfectionChronic Hepatitis B Virus InfectionChronic Hepatitis bFor Treatment of Chronic Hepatitis B Virus InfectionHepatitis B, ChronicPeg-IFNα
Phase 1
Phase 2
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
TerminatedNCT04781647
Start: 2021-02-18End: 2022-12-02Updated: 2023-10-06
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Active, not recruitingNCT04856085
Start: 2021-07-11End: 2026-03-31Updated: 2025-10-21
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
RecruitingNCT05771402
Start: 2023-10-10End: 2026-12-31Target: 120Updated: 2025-09-11
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
Active, not recruitingNCT05970289
Start: 2023-08-22End: 2026-02-28Updated: 2025-09-05
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Active, not recruitingNCT06491563
Start: 2024-08-06End: 2027-06-30Target: 150Updated: 2024-12-30
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
RecruitingNCT06650852
Start: 2024-10-31End: 2027-07-31Target: 250Updated: 2025-05-23